Assessment of CYP1A2 activity in clinical practice: why, how, and when?
about
Urinary melatonin concentration and the risk of breast cancer in Nurses' Health Study IIIndividualizing drug dosage with longitudinal data.Biomonitoring of complex occupational exposures to carcinogens: the case of sewage workers in Paris.Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort.The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction.Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine.Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumptionStructure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Novel natural inhibitors of CYP1A2 identified by in silico and in vitro screening.Development and validation of a reversed-phase HPLC method for CYP1A2 phenotyping by use of a caffeine metabolite ratio in saliva.Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.Effects of long-term smoking on the activity and mRNA expression of CYP isozymes in rats.Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments.Paraxanthine: Connecting Caffeine to Nitric Oxide Neurotransmission.Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women.Inhibition of Cytochrome P450 by Propolis in Human Liver Microsomes.Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.Curative Effects of ZHENG-Based Fuzheng-Huayu Tablet on Hepatitis B Caused Cirrhosis Related to CYP1A2 Genetic Polymorphism.Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake.Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.Carbonated soft drinks alter hepatic cytochrome P450 isoform expression in Wistar rats.Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Blood pressure in relation to coffee and caffeine consumption.Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.Inhibitory mechanisms of celastrol on human liver cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4.Activity of cytochrome P450 1A2 in relation to hepatic iron accumulation in transfusion-dependent β-thalassaemia major patients.In-vitro and in-vivo evaluations of cytochrome P450 1A2 interactions with nuciferine.Tacrine treatment at high dose suppresses the recognition memory in juvenile and adult mice with attention to hepatotoxicity.Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats.Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism.Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation.Letter in Reply to Arno et al. "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism".A genome-wide association study in the Japanese population identifies the 12q24 locus for habitual coffee consumption: The J-MICC Study.Answer to the Letter to the Editor Concerning "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism".The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis.
P2860
Q23921999-F69C93BB-DA44-4CAF-B2DF-B2361F9E45B2Q31108602-E6EF1EF0-1EEE-42DC-963E-B62FD990CE95Q33322926-F2C9C7E2-AD23-459A-950E-10CAF65720F4Q33722863-53FBD711-BAF8-42CD-98D0-2FEF1F6EED2DQ34367117-A3B78BBC-E856-4133-8D96-4A42E0166FCFQ34533895-3B8D74A9-56A6-4F21-A7CE-7A6E84C2FC3CQ34829535-D625C1DA-D0C9-4193-8CAB-0F5E3B351C34Q35015993-1C323E34-28C9-4669-965F-3DE071BFEB49Q35048610-7FEA93B6-2DDB-4962-ADEF-81FD2146B347Q35609358-B1F0F54E-984A-48B0-AC4F-808FBF132878Q35827758-3301EB5B-DC38-466D-AE27-D92612A43B75Q36254435-C8CA8833-7FEC-4067-91D9-1253D5C29CC2Q36662888-4A4B6158-D28D-4570-89E8-941A21A90B09Q36924618-78896C19-8866-4168-83D3-BEA0B146C4C2Q37071422-0CC09430-0D63-4A0E-A401-C0FB36DD7D3BQ37097643-2267F0E0-9132-4240-BC2D-85BB0BC8842AQ37157901-12C74AF5-10ED-4073-B2B5-4EA4A041FAB4Q37298904-5095B8F1-ABF7-417A-B342-607B1CFB6A4CQ37315406-BC94066A-F0A0-4563-B9F5-923068A96873Q37378059-7D8608FA-7569-4BD0-B1CD-462F70E7AB87Q37406300-05A7C0BA-A89D-4A9B-9C47-A723FDA18A5EQ37793826-C307D9C9-79C7-4F85-94A6-B407E95B8B8BQ37807282-9DE635C0-817F-452B-9547-BD324E80212FQ38028549-86471851-FB71-46D1-9819-0C712BDD189BQ38056972-A7F59686-73C4-4ADB-A2AF-362DC983A16CQ38103885-04D5D414-6B34-403B-94DA-31B0ED369DC2Q38236743-01E3FE76-2400-4375-959D-8D48B81FF810Q39952865-FD4A888D-2A2A-4F59-AFB3-923C5C4F76A4Q41155867-49F916DB-5FA9-47C1-89A6-89F3CF6D6A81Q41730972-9F210875-889A-4F7E-8834-CFC3B72E3263Q42978371-3B5F57D2-85B7-4492-A2B4-29C0B5EAC1A2Q43325239-CBC8563A-D63C-4433-8AA9-2A480E1821E1Q45325050-911AE538-9C46-4610-91E9-2B8783C33B80Q46007459-829E22A3-F8A3-4061-BFDD-1EF6C2405288Q46587398-C79FEC86-2850-4EA2-B5B7-854B744ED282Q46731517-77F41C0A-ECB4-46D4-AE84-52D5113E4F0EQ48170893-B51764C0-D2B3-4393-AE96-A104553FC961Q48171456-6CFE3DB7-C484-4B04-A296-5A572B063018Q48177069-AD8FE4E1-1903-44F4-BC7C-F8C66A1B3C0DQ49546782-A4464543-4D4B-44AC-94A2-FCB793B6F4BD
P2860
Assessment of CYP1A2 activity in clinical practice: why, how, and when?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Assessment of CYP1A2 activity in clinical practice: why, how, and when?
@ast
Assessment of CYP1A2 activity in clinical practice: why, how, and when?
@en
type
label
Assessment of CYP1A2 activity in clinical practice: why, how, and when?
@ast
Assessment of CYP1A2 activity in clinical practice: why, how, and when?
@en
prefLabel
Assessment of CYP1A2 activity in clinical practice: why, how, and when?
@ast
Assessment of CYP1A2 activity in clinical practice: why, how, and when?
@en
P1476
Assessment of CYP1A2 activity in clinical practice: why, how, and when?
@en
P2093
Alexander Jetter
P304
P356
10.1111/J.1742-7843.2005.PTO_973160.X
P50
P577
2005-09-01T00:00:00Z